Promoted Content
Promoted Content

Find Novel Oncology Drugs in Clinical Development in CHINA

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): KM257

            Therapeutic Area: Oncology Product Name: KM257

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Xuanzhu Biopharmaceutical

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition January 27, 2021

            Details:

            Combio Pharmaceutical product pipeline already has 12 products under development, of which KM257/252 is a bispecific antibody drug for cholangiocarcinoma, breast cancer, gastroesophageal cancer, etc.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CAR-T cell therapy

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: National Institutes of Health

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 12, 2021

            Details:

            As a result of the collaboration, Adagene discovered antibodies that Dr. Child’s laboratory has turned into a CAR-T cell therapy candidate for the potential treatment of renal cell carcinoma, the most common type of kidney cancer in adults, according to Frost & Sullivan.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tislelizumab

            Therapeutic Area: Oncology Product Name: BGB-A317

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation

            Deal Size: $2,200.0 million Upfront Cash: Undisclosed

            Deal Type: Collaboration January 11, 2021

            Details:

            Novartis Pharma will develop, manufacture and commercialize BeiGene’s anti-PD-1 antibody tislelizumab in the United States, Canada, Mexico, member countries of the European Union, United Kingdom, Norway, Switzerland, Iceland, Liechtenstein, Russia, and Japan.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): FCN-338

            Therapeutic Area: Oncology Product Name: FCN-338

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Eli Lilly

            Deal Size: $440.0 million Upfront Cash: $40.0 million

            Deal Type: Licensing Agreement October 30, 2020

            Details:

            Lilly gains exclusive rights to develop and sell FCN-338 in all countries and regions except for Mainland China, Macao, and Hong Kong. Fochon reserves all right to research, develop, register, manufacture, and market FCN-338 in Mainland China, Macao, and Hong Kong.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: WuXi Biologics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration October 10, 2020

            Details:

            Antengene and WuXi Biologics will make full use of their extensive resources and professional capabilities to accelerate the research and development of first-in-class or best-in-class innovative cancer therapies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): WJ1075

            Therapeutic Area: Oncology Product Name: WJ1024

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Shanghai Junshi Biosciences

            Deal Size: $69.2 million Upfront Cash: $5.2 million

            Deal Type: Collaboration September 16, 2020

            Details:

            Wigen Biomedicine will transfer its 50% interest in four of its drug candidates, XPO1 inhibitor, Aurora-A inhibitor, EGFR-exon20 inhibitor, and 4th generation EGFR inhibitor. Junshi will be granted the exclusive rights for production and commercialization for these drugs.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Hillhouse Capital Group

            Deal Size: $418.0 million Upfront Cash: Undisclosed

            Deal Type: Private Placement September 04, 2020

            Details:

            The Company will receive all proceeds from the private placement and intends to utilize them to fund the ongoing and planned research and clinical programs globally as well as the development of its commercialization capabilities in China.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Methotrexate

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 07, 2020

            Details:

            The research highlights a Methotrexate-loaded microvesicles tumor therapy for cholangiocarcinoma, approved for clinical use has shown significant efficacy and safety in the treatment of cholangiocarcinoma.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 16, 2020

            Details:

            Phanes Therapeutics has developed a proprietary bispecific antibody technology platform, PACbodyTM, which enables construction of a bispecific antibody using any pair of monoclonal antibodies while maintaining the IgG-like structure.